BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.
An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
SOURCE BioMarin Pharmaceutical Inc.
Mentioned In This Article
Latest News
| 7 hours | |
| Aug-19 | |
| Aug-19 | |
| Aug-18 | |
| Aug-18 | |
| Aug-18 | |
| Aug-18 | |
| Aug-12 | |
| Aug-10 | |
| Aug-07 | |
| Aug-06 | |
| Aug-06 | |
| Jul-30 | |
| Jul-28 |
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
BMRN
Pharmaceutical Technology
|
| Jul-27 |
